GS Investments’s Nektar Therapeutics NKTR Stock Holding History

GS Investments’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,333	Closed	-$270K	–	154
2021 Q4	$270K	Hold	1,333	–	–	0.13%	83
2021 Q3	$359K	Buy	+1,333	New	+$321K	0.19%	76
2021 Q1	–	Sell	-1,260	Closed	-$321K	–	101
2020 Q4	$321K	Buy	+1,260	New	+$326K	0.31%	66
2020 Q3	–	Sell	-3,613	Closed	-$1.26M	–	90
2020 Q2	$1.26M	Hold	3,613	–	–	1%	32
2020 Q1	$967K	Buy	3,613 +20	+0.6%	+$6.19K	0.95%	34
2019 Q4	$2.63M	Sell	3,593 -20	-0.6%	-$5.8K	2.18%	13
2019 Q3	$987K	Hold	3,613	–	–	0.72%	42
2019 Q2	$1.93M	Hold	3,613	–	–	1.58%	26
2019 Q1	$1.82M	Buy	3,613 +13	+0.4%	+$7.7K	1.43%	30
2018 Q4	$1.77M	Hold	3,600	–	–	1.49%	26
2018 Q3	$3.29M	Hold	3,600	–	–	2.3%	10
2018 Q2	$2.64M	Buy	3,600 +133	+4%	+$153K	1.97%	15
2018 Q1	$5.53M	Sell	3,467 -317	-8%	-$408K	4.05%	4
2017 Q4	$3.39M	Sell	3,784 -3	-0.1%	-$1.77K	2.59%	9
2017 Q3	$1.36M	Buy	3,787 +356	+10%	+$111K	1.09%	36
2017 Q2	$1.01M	Buy	+3,431	New	+$992K	0.75%	40

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

GS Investments's NKTR Position: Q1 2022 in Review

GS Investments sold out of Nektar Therapeutics (NKTR) in Q1 2022, closing a stake of 1,333 shares — an estimated $270K sold.

GS Investments first reported a position in NKTR in Q2 2017 and held it in 16 quarters. The position peaked at $5.53M in Q1 2018. 239 funds tracked by Wall St. Rank hold NKTR as of Q1 2022.

GS Investments reported no remaining Nektar Therapeutics position as of Q1 2022 after selling out during the quarter.
GS Investments sold 1,333 Nektar Therapeutics shares in Q1 2022, an estimated $270K.
GS Investments first reported a position in Nektar Therapeutics in Q2 2017 and held it in 16 quarters.
GS Investments's Nektar Therapeutics position peaked at $5.53M in Q1 2018.
239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2022.

Based on GS Investments's 13F filing for Q1 2022, filed 26 Apr 2022.